Drugmaker Merck has reported that the Food Drug Administration has rejected a new cholesterol drug combo dubbed the “Son of Vytorin.” According to Forbes, the drug is a “combination of atorvastatin, the active ingredient in Lipitor, and ezetimibe, the on-patent ingredient in its Zetia and Vytorin products,” and the combo shows promise for patients who [...]
Merck Cholesterol Drug Combo Rejected by FDA, Additional Data Requested is a post from: The Inquisitr